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Abstract
Background CCL20, the single chemokine ligand for CCR6,
contributes to recruiting CCR6-expressing memory B cells,
memory Tcells, Th17 cells and dendritic cells, and is involved
in regulating immune responses, homeostasis, and inflamma-
tion in mucosal tissues.
Methods CCL20 messenger RNA (mRNA) expression was
analyzed in the conjunctival epithelium in an in vivo study of
patients with vernal keratoconjunctivitis (VKC group) and
healthy volunteers (control group) using impression cytology.
In vitro analysis of CCL20 mRNA was performed using
cultured conjunctival epithelial cells (CECs). Real-time poly-
merase chain reaction was used to assess IL-8 and eotaxin-2
mRNA expression for comparison with CCL20 mRNA
expression.
Results In the control group, CCL20 mRNA expression was
present in all conjunctival locations. However, CCL20mRNA
expression was significantly higher in the upper palpebral
conjunctiva in the severe VKC group than in the mild VKC
and control groups (p<0.05, Steel test). In vitro stimulation of
CECs with lipopolysaccharide (LPS) significantly increased
CCL20 expression in a concentration-dependent manner that
was significantly correlatedwith expression of IL-8 (p<0.001,
Spearman’s rank correlation coefficient), but not eotaxin-2.
Conclusion We conclude that CCL 20 mRNA expression in
the conjunctival epithelium plays a crucial role in regulating
homeostasis at the ocular surface and in exacerbation of VKC.
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Introduction
Chemokines are involved in acute and chronic inflammatory
processes, as they attract neutrophils, monocytes, B cells, and
T cells to the inflammation site via their corresponding che-
mokine receptors. Recent reports have shown that the con-
junctival epithelium is an important chemokine producer un-
der pathophysiologic conditions observed in ocular surface
diseases [1, 2]. In allergic conjunctival diseases, eotaxin-1 and
eotaxin-2 expression in the conjunctival epithelium is crucial
for inducing allergic inflammation in the conjunctiva through
eosinophil recruitment [3]. Furthermore, conjunctival epithe-
lial cells contribute to the pathogenesis of ocular surface
diseases by producing proinflammatory cytokines such as
interleukin (IL)-8 [4, 5]. IL-6 and IL-8 can be detected in the
tears of healthy individuals [6]. Thus, chemokines function as
inflammatory and homeostatic factors at the ocular surface.
CCL20/macrophage inflammatory protein-3 alpha (MIP-3α)
has recently been identified as an important chemokine in the
regulation of homeostasis and inflammation in mucosal tis-
sues. CCL20, which is the single chemokine ligand for CCR6,
contributes to these processes by recruiting CCR6-expressing
memory B cells [7–9], CD45RO+ memory Tcells [10], IL-17-
secreting CD4+ Tcells (Th17) [11], and dendritic cells such as
Langerhans cells [12] .
Proliferative conjunctival lesions such as giant papillae are
an important feature of severe allergic conjunctival diseases.
Histological analysis of proliferative conjunctival lesions has
demonstrated infiltration of many inflammatory cells such as
neutrophils, eosinophils, mast cells, and CD45RO+memory T
cells [13] in subconjunctival tissues in such diseases. Multiple
stimuli induce chemokine expression in the conjunctival
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epithelium. Chemokines in the conjunctiva, including
eotaxin-1, eotaxin-2, and eotaxin-3 induce eosinophilic infil-
tration, whereas IL-8 induces neutrophilic infiltration. CCL20
has been reported to be involved in Th17 cell invasion of the
ocular surface in a dry eye mouse model [14]. Data from this
mouse model suggest that CCL20 is associated with conjunc-
tival inflammation. However, the mechanisms underlying
CCL20 expression in the human conjunctival epithelium in
patients with allergic conjunctival diseases remain unknown.
This study aimed to investigate CCL20 mRNA expression
in the human conjunctival epithelium in vivo by using im-
pression cytology specimens from healthy individuals and
patients with vernal keratoconjunctivitis (VKC). In addition,
an in vitro study analyzing CCL20 mRNA expression in
cultured conjunctival epithelial cells (CECs) was performed.
Subjects and methods
This study was approved by the Nihon University School of
Medicine’s Ethics Committee for Clinical Study and adhered
to the tenets of the Declaration of Helsinki. The experimental
design of the clinical study consisted of an in vivo study using
impression cytology specimens and an in vitro study using
cultured CECs.
Analysis of in vivo CCL20/MIP-3α mRNA expression
in the conjunctival epithelium of healthy volunteers
and patients with vernal keratoconjunctivitis
Subjects
The subjects comprised 11 healthy volunteers (eight men and
eight women; mean±SD of age, 30.6±8.6 years) (control
group) and 11 patients who had VKC (11 men; mean±SD
of age, 23.1±10.4 years) (VKC group) and had been treated at
the Department of Ophthalmology, Nihon University Itabashi
Hospital, from June 2009 to July 2010. Demographic and
clinical data of patients with VKC are shown in Table 1.
According to the Japanese guidelines [15], we diagnosed
VKC in patients with both of proliferative conjunctival lesions
such as giant papillae or gelatinous limbal infiltration and
allergen-specific IgE antibodies in serum at initial diagnosis.
The enrolled VKC patients had one or several positive
allergen-specific IgE antibodies, such as those to house dust
mites or Japanese cedar pollen, detected in their serum using
ImmunoCAP® specific IgE (Thermo Scientific, Yokohama,
Japan). Patients who had VKC and had a history of systemic
corticosteroid and/or immunosuppressive drug treatment were
excluded from the study. Informed consent for participation
was obtained before enrolment. Conjunctival impression cy-
tology for the VKC group was performed for either the affect-
ed eye in unilateral cases or the more severely affected eye in
bilateral cases. Healthy volunteers (11 right eyes) who had
neither allergic diathesis nor a history of wearing contact
lenses were also recruited as controls.
CCL20 mRNA expression in the conjunctival epithelium
of healthy subjects and patients with VKC
In the first study, we investigated the differences in the con-
junctival localization of CCL20 mRNA expression in the
different control subjects. Impression cytology was performed
for the upper palpebral conjunctiva, lower palpebral conjunc-
tiva, and temporal bulbar conjunctiva, and local differences in
the CCL20 mRNA level were compared among all control
subjects.
In the second study, we investigated the differences in
CCL20 mRNA expression induced by allergic inflammation
between for the VKC and control groups. In the VKC group,
impression cytology was performed for the upper palpebral
conjunctiva, and pathological differences in the CCL20
mRNA level were compared between the VKC and control
groups.
Scoring of clinical severity in VKC patients
The clinical severity in VKC group patients was scored using
the 5-5-5 exacerbation grading scale [16]. The 5-5-5 exacer-
bation grading scale has been previously reported as a method
for measuring the severity of allergic conjunctival diseases.
With this scoring method, the clinical score is determined by
the total number of points. Five severe clinical findings are
given 100 points for each finding, five moderate clinical
findings are given 10 points for each finding, and five mild
clinical findings are given 1 point for each finding (Table 2).
Using this method, the patients with VKC were divided into
severe, moderate, and mild subgroups. Based on the 5-5-5
exacerbation grading scale, the VKC patients were divided
into three phases of clinical severity: severe (more than 200
points), moderate (100–200 points) and mild (less than 100
points). Because of the low overall number of cases, the
evaluated VKC subgroup was divided into the following
two subgroups: the severe subgroup consisted of VKC pa-
tients with both severe and moderate clinical severity, and the
mild subgroup consisted of VKC patients with mild clinical
severity.
Impression cytology
Impression cytology was performed after an instillation of
topical 0.4 % oxybuprocaine (Benoxil; Santen, Osaka,
Japan). Strips of nitrocellulose membranes (Millipore,
Bedford, MA, USA) were applied to the conjunctiva, pressed
gently by a glass rod, and then removed. The nitrocellulose
membrane was then preserved in RNAlater RNA Stabilization
Reagent (Qiagen, Hilden, Germany) until analysis.
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Real-time polymerase chain reaction
For detection of CCL20 mRNA expression by real-time po-
lymerase chain reaction (real-time PCR), total RNA from each
impression cytology specimen was harvested using an
RNeasy® Mini Kit (QIAGEN, Hilden, Germany) by follow-
ing the instructions in the manufacturer’s manual. cDNAwas
then synthesized using a High-Capacity cDNA Reverse
Transcription Kit (Life Technologies Japan, Tokyo, Japan)
according to the manufacturer’s instructions.
Real-time PCR was performed using a commercial PCR
master mix (TaqMan Universal PCR Master Mix; Life
Technologies Japan) and predesigned primers (Life
Technologies Japan) for CCL20 (Hs00355476_m1), IL-8
(Hs99999034_m1), and eotaxin-2 (Hs00171082_m1).
Samples were analyzed using a real-time PCR system (Step
One PlusTM; Life Technologies Japan) and comparative
threshold (Ct) values were obtained. Target Ct values were
normalized to those of GAPDH (Hs99999905_m1) from the
same sample. Data were analyzed by the ΔΔCT method.
Statistical analysis
CCL20 mRNA expression in impression cytology specimens
was evaluated by the nonparametric Steel-Dwass test for
investigation of differences in conjunctival localization
Table 2 Guidelines for the 5-5-5 exacerbation grading scale used to score allergic conjunctival diseases
Exacerbation grading scale *
Grade of Clinical sign 100-point grade 10-point grade 1-point grade
Active giant papillae 1) Blepharitis Papillae at the upper palpebral
conjunctiva
Gelatinous infiltrates of the limbus Papillary proliferation with velvety
appearance
Follicular lesion at the lower
palpebral conjunctiva
Clinical signs Exfoliative epithelial keratopathy Horner-Trantas spots Hyperemia of the palpebral
conjunctiva
Shield ulcer Edema of the bulbal conjunctiva Hyperemia of the bulbal conjunctiva
Papillary proliferation at the lower
palpebral conjunctiva
Superficial punctate keratopathy Lacrimal effusion 2)
Score 100 points×number of positive signs 10 points×number of positive signs 1 point×number of positive signs
Range 0–500 points 0–50 points 0–5 points
*: 5-5-5 exacerbation grading scale [16]
1) “Active giant papillae”means the giant papillary proliferation that spreads in hemispherical shape with mucous discharge, but mucous discharge is not
essential. Giant papillae with flatness and poor inflammation findings are excluded
2) “Lacrimal effusion” refers to the epiphora or tear meniscus increase caused by eye irritation
Table 1 Demographic and clinical data of patients with VKC
Case Age (year) Sex Type of VKC Clinical score* Severity Stage of VKC Complication of AD Therapeutic medicine
1 30 Male Mix 223 severe Active + DSCG, TA
2 20 Male Palpebral 22 Mild Stable + DSCG, TA
3 7 Male Mix 113 Moderate Active + DSCG, TA
4 34 Male Mix 23 Mild Stable + DSCG, TA
5 41 Male Palpebral 113 Moderate Stable DSCG, CsA
6 21 Male Palpebral 23 Mild Stable DSCG, TA
7 27 Male Mix 23 Mild Stable + DSCG, TA
8 30 Male Palpebral 223 severe Active + DSCG, TA
9 19 Male Mix 124 Moderate Active + DSCG, TA
10 9 Male Palpebral 112 Moderate Stable None
11 16 Male Mix 123 Moderate Active DSCG, TA
*: 5-5-5 exacerbation grading scale [reference 16)]
AD: atopic dermatitis, VKC: vernal keratoconjunctivitis, DSCG: disodium cromoglycate ophthalmic solution, TA: Tacrolimus ophthalmic solution,
CsA: Cyclosporine A ophthalmic solution
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changes (first study), and the Steel test was used to
investigate of differences in allergic inflammation (sec-
ond study). We evaluated the correlation between
CCL20 mRNA and IL-8 mRNA levels and that between
CCL20 mRNA and eotaxin-2 mRNA levels by using a
nonparametric correlation method, the Spearman corre-
lation coefficients. p <0.05 was considered to indicate
statistical significance.
In vitro study evaluating CCL20/MIP-3α mRNA expression
in cultured human conjunctival epithelial cells
Human conjunctival epithelial cell culture A human con-
junctival epithelial cell line (Wong-Kilbourne derivative
of Chang conjunctiva, clone 1-5c-4, CCL-20.2;
American Type Culture Collection [ATCC], Manassas,
VA, USA) was cultured under standard conditions (hu-
midified atmosphere of 5 % CO2 at 37 °C) in a mixed
medium containing Ham’s F12 and Dulbecco’s modified
Eagle’s medium (DMEM; 1:1; Life Technologies Japan)
supplemented with recombinant epidermal growth factor
(10 ng/mL; Life Technologies Japan), recombinant insu-
lin (5 μg/mL; Life Technologies Japan), dimethyl sulf-
oxide (0.5 %; Sigma-Aldrich Japan, Tokyo, Japan), gen-
tamicin (40 μg/mL; Schering-Plough, Osaka, Japan),
penicillin G (100 U/mL; MSD, Tokyo, Japan), and
10 % fetal bovine serum (Life Technologies Japan) in
35-mm tissue culture dishes (Falcon 3001; Becton
Dickinson, Tokyo, Japan). The cultured CECs were
detached after incubation in 0.25 % trypsin and 0.5 %
EDTA (Sigma-Aldrich Japan) after they reached
confluency. The resuspended cells were then seeded in
24-well plates (ASAHI GLASS, Tokyo, Japan) at 104
cells per well and cultured until they reached conflu-
ence. Confluent CECs were then exposed to various
concentrations of lipopolysaccharide (LPS) (0, 20, 40,
80, and 160 μg/mL) for 4 h and analyzed for mRNA
expression.
Real-time PCR
Real-time PCR for CCL20 mRNA expression in human cul-
tured CECs was performed using the same method described
above.
Statistical analysis
CCL20 mRNA expression in cultured human CECs
were evaluated using the nonparametric Steel test.
Spearman correlation coefficients were used to evaluate
whether CCL20 mRNA expression was correlated with
IL-8 mRNA expression. p <0.05 was regarded as statis-
tically significant.
Results
CCL20 mRNA expression in the conjunctival epithelium
in the control group
CCL20mRNA expression in healthy volunteers was detected in
impression cytology specimens obtained from the upper palpe-
bral, lower palpebral, and temporal bulbal conjunctiva. The
(median [range]) CCL20 mRNA level in the upper palpebral
conjunctiva, lower palpebral conjunctiva, and temporal bulbal
conjunctiva was 1.20 (0.10–15.3), 16.1 (3.54–27.0), and 0.18
(0.08–0.89), respectively. CCL20 mRNA expression in the
lower palpebral conjunctiva was significantly higher than that
in the upper palpebral conjunctiva (Steel-Dwass test, p<0.01;
Fig. 1). Furthermore, the CCL20 mRNA levels in the upper
palpebral conjunctiva were significantly higher than those in the
temporal bulbal conjunctiva (Steel-Dwass test, p<0.01; Fig. 1).
CCL20 mRNA expression in the upper tarsal conjunctiva
in the VKC and control groups
The VKC group was divided into the severe VKC and mild
VKC subgroups according to the clinical score (Table 1, Fig. 2).
The (median [range]) CCL20 mRNA levels in the upper pal-
pebral conjunctiva in the mild and severe VKC subgroups were
2.52 (0.28–5.70) and 46.7 (12.0–471), respectively. CCL20
mRNA expression in the severe VKC group was significantly
higher than that in the control group (Steel test, p<0.05; Fig. 3).
The CCL20, IL-8, and eotaxin-2 mRNA levels obtained in
the VKC group are shown in Table 3. The CCL20 mRNA
levels were significantly correlated with IL-8 mRNA levels
(Spearman’s correlation, r=0.83, p<0.01; Fig. 4), but not with
eotaxin-2 mRNA levels.
Fig. 1 CCL20 mRNA expression in the upper palpebral, lower palpe-
bral, and temporal bulbal conjunctiva. CCL20 mRNA expression was
high in the lower palpebral conjunctiva, upper palpebral conjunctiva, and
temporal bulbar conjunctiva. In particular, CCL20 mRNA expression
was significantly higher in the lower palpebral conjunctiva than in the
upper palpebral conjunctiva and temporal bulbar conjunctiva. **: Steel-
Dwass test, p<0.01
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CCL20 mRNA expression in cultured conjunctival epithelial
cells
Analysis of CCL20 mRNA expression in LPS-stimulated
CECs indicated a significant concentration-dependent in-
crease in CCL20 expression induced by LPS (Fig. 5a), which
was correlated with IL-8 mRNA expression (Fig. 5b).
Discussion
CCL20 is a C-C chemokine associated with the migration of
CCR6-expressing inflammatory cells such as dendritic cells,
B cells, memory Tcells, and Th17 cells. These CCR6-positive
immunocytes are thought to be involved in immune re-
sponses, homeostasis [17], and inflammation [18] in mucosal
tissues [19]. Therefore, evaluation of local CCL20 expression
in the ocular surface is thought to be important for understand-
ing the pathologic features of inflammatory conjunctival dis-
eases, including infectious conjunctivitis and allergic conjunc-
tival diseases.
Initially, we assessed CCL20 mRNA expression in the
ocular surface of healthy volunteers by using the impression
cytology method. Because biopsy samples including superfi-
cial epithelial cells of the ocular surface can be obtained with
this method, this is the most useful method for analyzing the
pathologic conditions of the local conjunctiva, as it enables the
measurement of chemokine mRNA expression in cytology
specimens. Our results showed that CCL20 mRNA is consti-
tutively present in the conjunctival epithelium. These results
agree with those of previous reports demonstrating that
CCL20 is involved in mucosal homeostatic maintenance [17].
We also found that CCL20 mRNA expression levels were
higher in the palpebral conjunctiva than in the bulbar conjunc-
tiva. In previous studies, CCL20 expression in the intestinal
epithelium has been reported to strongly increase in the
lymphoepithelium and M cells of the Peyer’s patch [20].
Alternatively, human conjunctiva-associated lymphoid tissue
(CALT), which is functionally equivalent to Peyer’s patches,
is present mainly in the palpebral conjunctiva [21, 22].M-cell-











(112–223) P < 0.01
*: Clinical score: 5-5-5 exacerbation grading scale (see table 2)
**: Mann-Whitney U test
b-1                                       b-2
5-5-5 exacerbation grading scale                
22 points 223 points
Fig. 2 Vernal
keratoconjunctivitis (VKC)
subgroup. a: Characteristics of the
VKC subgroups. b:
Representative photograph of a
patient withmild VKC (b-1) and a
patient with severe VKC (b-2).
The criterion for severe VKC was
a clinical score greater than 100
points and for mild VKC was a
clinical score lower than 100
points
Fig. 3 CCL20 mRNA expression in the control and VKC groups. In the
upper palpebral conjunctiva, CCL20mRNA expression was significantly
higher in the severe VKC group than in the control group (p<0.05, Steel
test). CCL20 mRNA expression did not significantly differ between the
control group and mild VKC group. *: p<0.05, Steel test. NS: not
significant
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covering CALT [23, 24]. Furthermore, the conjunctival folli-
cles formed mainly on lower palpebral conjunctiva have char-
acteristics similar to those of CALT. Therefore, in our study,
the anatomical characteristics of the conjunctiva may have
influenced CCL20 mRNA expression in the palpebral con-
junctiva, resulting in higher levels of CCL20 expression than
those in the bulbar conjunctiva.
In our study, we assessed CCL20 mRNA expression in the
upper palpebral conjunctiva where papillary proliferation is
observed in patients with VKC. CCL20 mRNA expression in
the upper palpebral conjunctiva was significantly higher in the
severe VKC group than in the control group. These results
show that CCL20 is constantly expressed in the conjunctival
epithelium and that its expression increases when allergic
inflammation in the conjunctiva is aggravated. Several reports
have suggested that inflammatory cells express CCR6, which
is a ligand of CCL20 associated with allergic inflammation
[25]. Lukacs et al. reported that CCR6-deficient mice had
reduced airway resistance, fewer eosinophils around the air-
way, lower interleukin-5 levels in the lung, and reduced serum
IgE levels [26]. Furthermore, local expression of CCL20 in
allergic and immunological disorders has been demonstrated
by Reibman et al., who showed that airway epithelial cells
release CCL20/MIP-3 alpha in response to cytokines and
ambient particulate matter in cultured human bronchial airway
epithelial cells [27]. Furthermore, increased CCL20 levels
have been shown in sputum obtained from patients with
severe asthma. Increased CCL20 expression in keratinocytes
of patients with psoriasis has been reported, and the
contribution of CCR6-positive Th17 cells to the pathol-
ogy of inflammatory diseases has been suggested clini-
cally [28, 29]. Therefore, the CCL20/CCR6 axis is
thought to be an important local factor involved in
regulating the pathology of allergic inflammation in
patients with severe VKC.
The conjunctival epithelium produces various chemokines
as a defence mechanism against antigen invasion from the
external environment. IL-8, a proinflammatory cytokine pro-
duced by the conjunctival epithelium [4], is involved in
biophylaxis and induces neutrophilic migration. In addition,
eotaxin is known to be an important chemokine in the pathol-
ogy of allergic reactions at the ocular surface. Eotaxin-1/
CCL11, eotaxin-2/CCL24, and eotaxin-3/CCL26 are part of
the eotaxin subfamily, and each eotaxin subfamily induces
eosinophilic migration through CCR3. We had previously
reported that eotaxin-2 levels are significantly increased in
the tears of patients with VKC and that this increase is signif-
icantly correlated with the concentration of eosinophil cationic
protein in tears [3]. Our in vivo study on the conjunctival
epithelium of patients with VKC indicated that CCL20 ex-
pression was significantly correlated with the expression of
IL-8, but not eotaxin-2. The results of this in vivo study were
validated by the in vitro study using cultured conjunctival
epithelial cells. To stimulate the conjunctival epithelial cells,
Fig. 4 Correlation between CCL20 mRNA expression and IL-8 mRNA
expression in the VKC group. CCL20 mRNA expression was signifi-
cantly correlated with IL-8mRNA expression in the conjunctiva (r=0.83,
p<0.01, Spearman’s rank correlation coefficient)
Fig. 5 CCL20 mRNA
expression in cultured
conjunctival epithelial cells. a: In
the cultured conjunctival
epithelial cells, CCL20 mRNA
expression increased in a dose-
dependent manner in response to
lipopolysaccharide (LPS)
stimulation (p<0.05, Steel test).
b: In the cultured conjunctival
epithelial cells stimulated with
LPS, CCL20 mRNA expression
was significantly correlated with
IL-8 mRNA expression (r=0.82,
p<0.001, Spearman’s rank
correlation coefficient)
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we used LPS, which induces IL-8 production and is an endo-
toxin found in the outer membrane of gram-negative bacteria.
CCL20 mRNA levels were significantly correlated with IL-8
levels, similar to the in vivo results. These results demonstrate
that normal flora in the conjunctival sac and pathogenic bac-
teria of infectious keratoconjunctivitis may be involved in
regulating CCL20 expression in the conjunctival epithelium.
Epithelial CCL20 expression in the intestinal epithelia is
reported to increase in response to LPS stimulation [30].
Therefore, the CCL20/CCR6 axis may be strongly associated
with exacerbation of VKC in response to components of the
external environment, including bacteria.
Further investigation is necessary to enable practical use of
CCL20 mRNA expression in superior palpebral conjunctiva
as a biomarker of inflammatory or infectious conjunctival
diseases.
Therefore, we conclude that CCL20 mRNA expression in
the conjunctival epithelium plays a crucial role in homeostasis
at the ocular surface and in exacerbation of VKC. Further
studies are necessary to determine the molecular mechanism
by which CCL20 expression in the conjunctival epithelium is
enhanced by the external environment.
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